Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 709 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Decadron Clear all

Conditions: Multiple Myeloma
Interventions: Acetaminophen, Biospecimen Collection, Dexamethasone, Electronic Health Record Review, Famotidine, Loratadine, Methylprednisolone, Montelukast, Motixafortide, Pheresis, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor; Drug · Procedure · Other + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Epiretinal Membrane, Macular Edema
Interventions: Dexamethasone Intravitreal Implant; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Chesterfield, Missouri • St Louis, Missouri

Conditions: Spine Fusion
Interventions: Prednisone 20 Mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Waldenstrom's Macroglobulinemia
Interventions: pomalidomide, dexamethasone, rituximab; Drug
Lead sponsor: Steven P. Treon, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Arterial Diseases
Interventions: Dexamethasone Sodium Phosphate Injection, USP; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
Interventions: Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more

Conditions: Myeloma
Interventions: Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Selinexor; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 27
States / cities: Irvine, California • Laguna Hills, California • Orange, California + 22 more

Conditions: Obstructive Sleep Apnea
Interventions: Ketorolac, Standard of Care; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 12
States / cities: Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 9 more

Conditions: Asthma, Status Asthmaticus, Wheezes
Interventions: Dexamethasone, Prednisone; Drug
Lead sponsor: University of Florida; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: Marizomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Refractory Multiple Myeloma
Interventions: azacitidine, lenalidomide, dexamethasone, DNA methylation analysis, gene expression analysis, bone marrow aspiration, immunohistochemistry staining method, reverse transcriptase-polymerase chain reaction, flow cytometry; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Hip Arthropathy
Interventions: Nerve Block, Periarticular Injection (PAI), Ropivacaine, Dex; Procedure · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma
Interventions: ACE-011, Lenalidomide, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Waldenstrom's Macroglobulinemia
Interventions: Dexamethasone, Carfilzomib, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Macular Edema, Vitrectomy
Interventions: Dexamethasone; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Amyloidosis, Systemic Light Chain Amyloidosis
Interventions: Carfilzomib, Dexamethasone; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Duarte, California • Stanford, California • Atlanta, Georgia + 6 more

Conditions: Cervical Radiculopathy, Cervical Spondylosis, Disk, Herniated
Interventions: Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions: Dexamethasone, 0.4mg, Prednisone acetate, Control; Drug · Other
Lead sponsor: Warrenville Eyecare; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Warrenville, Illinois

Conditions: Dry Eye Syndromes
Interventions: Lifitegrast 5% Ophthalmic Solution, Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Eye Surgeons of Indiana; Network
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Myeloma
Interventions: Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy; Drug · Other · Behavioral + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Steroids After Spine Fusion Surgery

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Effect of Ketorolac on Post Adenotonsillectomy Pain

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Steroids in Children Hospitalized With Asthma

Marizomib Central Nervous System (CNS)

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Effectiveness of Cervical Transforaminal Epidural Steroid Injection

Dextenza With ILUX for Treatment of MGD

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy